Informations sur le produit
GNE-317 is a cancer therapeutic that inhibits the activity of CDK4/6 and is currently in phase II clinical trials. GNE-317 has been shown to be effective in inhibiting tumor growth in mice with metastatic melanoma. The mechanism of action of GNE-317 is by binding to CDK4/6 and inhibiting their activity, which prevents phosphorylation of effector proteins such as S6 kinase. This inhibition leads to a decrease in cell proliferation and an increase in apoptosis.
GNE-317 has been shown to inhibit the growth of human breast cancer cells without affecting normal cells. It also inhibits Hdac, a protein involved in cell signaling pathways that can lead to uncontrolled cell growth, which may be due to its ability to inhibit histone deacetylation.
Propriétés chimiques
Question d’ordre technique sur : 3D-UFC07692 GNE-317
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages
